By the numbers
0.0M
Medical communitymembers
0K
Curated contentpieces
0M+
Monthlypageviews
By the numbers
0.0M
Medical communitymembers
0K
Curated contentpieces
0M+
Monthlypageviews
TribeMD
Eventos
Notícias em alta
May 15, 2026
HF 2026: Cardio-Oncology as One of the Highlights of the European Heart Failure Congress
CardioOncology
CardioOncologyMay 15, 2026
5 min read
HF 2026: Cardio-Oncology as One of the Highlights of the European Heart Failure Congress
The European Heart Failure Congress attracted more than 6,000 attendees from around the world. One of the most prominent areas at the congress was cardio-oncology. In addition to exclusive sessions featuring global leaders, research covering various aspects of cardio-oncology was presented, bringing stronger evidence to clinical practice. Two highlights from the congress:<span sty
CardiometabolicsMay 15, 2026
5 min read
Precision Medicine and Cardiometabolism as Major Highlights of Heart Failure 2026
Precision medicine is the new frontier of medicine, and Heart Failure 2026 was no exception.A major highlight in this area goes beyond genetic knowledge to encompass phenotype characteristics, which can be better identified through new technologies (e.g., artificial intelligence) and modulated by the patient's lifestyle and environment.<p class
CardiologyMay 15, 2026
3 min read
Main Cardiac Intensive Care Studies Presented as Late Breaking Science at Heart Failure 2026
Cardiac intensive care, recently recognized as a specialty area in Brazil, was one of the most prominent topics at HF 2026. Several studies presented at Late Breaking Science sessions focused on this interface between cardiology and intensive care medicine. Here are some highlights:Highlight 1: HeartMate 3 vs. Cardiac Transplantation</
OncologyMay 15, 2026
5 min read
SUMMIT Basket Trial: Targeted Therapy for HER2-Mutated Metastatic Triple-Negative Breast Cancer
Triple-negative breast cancer remains one of the most challenging subtypes in breast oncology, due to its greater biological aggressiveness and historically limited availability of targeted therapies. In recent years, immunotherapy and antibody-drug conjugates have expanded therapeutic options, but an important gap remains for patients whose tumors harbor actionable genomic alterations. In this context, activating mutations in HER
Medical leaders
Browse our partner doctors' contents